Compare Dolby Laboratories, Inc. (DLB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Sanofi SA — how do they compare? Dolby Laboratories, Inc. trades at $61.2 (market cap $5.75B), while Sanofi SA trades at $43.65 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 18.1× Dolby Laboratories, Inc.'s market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| DLB | SNY | |
|---|---|---|
Market Cap | $5.75B | $104.30B |
Sector | Industrials | Health |
52-Week High | $75.62 | $52.34 |
52-Week Low | $48.51 | $41.33 |
Enterprise Value | $5.12B | $124.19B |
Dividend Yield | 2.35% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLB trades at $61.39, down 1.14% today, with a bullish technical signal from moving averages and a consensus analyst price target of $87.50. The company has beaten EPS estimates for the last four quarters, including Q2 2026, and maintains strong profitability with an 87.61% gross margin. Recent news highlights growth in Dolby Atmos and auto licensing, though revenue declined year-over-year in Q3 2026.
The outlook is positive with analyst support and operational strength, but risks include licensing volatility and near-term execution challenges. The stock offers upside to the price target, supported by cash flow growth and market expansion in audio-visual technologies.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
